Glaucoma Progression Articles & Analysis
16 news found
NORTH CHICAGO, Ill. and WAVRE, BELGIUM, July 20, 2022 – AbbVie (NYSE: ABBV) and iSTAR Medical SA, today announced a strategic transaction to further develop and commercialize iSTAR Medical’s MINIject® device, a next-generation minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma. This complementary alliance will support ...
MINIject® is the only commercially available supraciliary minimally invasive glaucoma surgery (MIGS) device. The two-year results indicated sustained, meaningful efficacy and favourable safety outcomes in patients with primary open-angle glaucoma. ...
Suppression of diurnal, or daily, fluctuations in IOP, is a significant and independent risk factor for the progression of glaucoma. In the Hispanic population subset of the GEMINI study, the unmedicated mean diurnal IOP was reduced from 22.8 mmHg (2.5) to 14.9 (3.6) at 12 months – also a 35% reduction, as with the larger study. ...
MINIject® is iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) implant and currently the only commercially available supraciliary MIGS device. ...
Recent Business Highlights Generated 2021 total revenue of $49.0 million, an increase of 77% compared to the prior year Generated fourth quarter 2021 total revenue of $14.7 million, an increase of 63% compared to the prior year period Expanded total gross margin to 87% in the fourth quarter 2021 versus 74% in the prior year period Received FDA 510(k) Clearance of the TearCare® System ...
(Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced that the first patient has been treated in the novel TRIDENT clinical trial, designed to demonstrate the OMNI Surgical System with higher volume as a safe and effective standalone treatment option, compared to implantation of iStent ...
The SBIR grant for IOP-Connect integration offers a path to effective IOP monitoring and control so that we can begin to determine what other factors affect glaucoma progression and vision loss.” “There is a misperception that it’s primarily later stage glaucoma patients who require more frequent monitoring and ...
Results from the study were presented by Russell Tait, PhD, Chief Executive Officer of PolyActiva, at the 11 th Annual Glaucoma 360 New Horizons Forum in San Francisco, CA. “The results of the low dose cohort demonstrate that the implant achieves a clinically meaningful IOP-lowering effect,” commented Associate Professor Michael Coote, MD, a leading ...
Commercial rollout continues following European approval in 2021 WAVRE, Belgium — 12 January 2022: iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announced initial positive progress of MINIject™ in its US STAR-V trial. MINIject is a potentially best-in-class minimally-invasive glaucoma surgery (MIGS) ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, today announced that the first patient has been enrolled in a pivotal clinical trial evaluating the Hydrus Microstent in patients with mild to moderate open-angle ...
(Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced publication in Clinical Ophthalmology of favorable data showing that microinvasive glaucoma surgery (MIGS) using the OMNI® Surgical System suppressed daily fluctuations in intraocular pressure (IOP) ...
The Latanoprost FA SR Ocular Implant is designed to substitute for daily drop therapy by providing sustained treatment from a single implant administration over a six-month period to treat glaucoma. Up to 46 percent of patients do not remember to use their eye drops or administer them poorly. Adherence to daily drop therapy is critical to slow progression of ...
LL-BMT1 is a therapeutic contact lens that delivers preservative-free bimatoprost to the eye to treat glaucoma for one week. After a productive Pre-IND meeting with the FDA, Leo Lens has now successfully completed GLP biocompatibility studies required by the FDA, secured a clinical research organization to oversee the initial human clinical trial, secured the clinical site, and ...
Injectsense’s first application is measurement of intraocular pressure (IOP), a glaucoma progression risk indicator. The IOP sensors, which have been tested in live animals, periodically send data to the cloud, providing physicians with clinically actionable information, keeping typically vulnerable glaucoma patients out of the ...
The Injectsense IOP-Connect system creates an organ-to-cloud data connection that enables the clinician to assess glaucoma therapy effectiveness at any time. The system is expected to provide unprecedented visibility into the IOP profile of the patient over time, and into previously unobserved changes that may affect glaucoma progression. ...
July 23, Chicago- PolyActiva Pty Ltd, a clinical-stage biotechnology company and leader in ocular drug delivery, has completed patient enrolment for its Phase I clinical trial to study safety and tolerability of its biodegradable, slow-release ocular implant for the treatment of glaucoma. PolyActiva's implant has the potential to revolutionise the treatment for millions of ...